Display options
Cite
Marec-Berard P, Segura-Ferlay C, Tabone MD, et al. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma. 2014;2014:475067doi: 10.1155/2014/475067.
Marec-Berard, P., Segura-Ferlay, C., Tabone, M. D., Pacquement, H., Lervat, C., Gentet, J. C., Schmitt, C., Gaspar, N., & Brugières, L. (2014). High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma, 2014475067. https://doi.org/10.1155/2014/475067
Marec-Berard, Perrine, et al. "High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group." Sarcoma vol. 2014 (2014): 475067. doi: https://doi.org/10.1155/2014/475067
Marec-Berard P, Segura-Ferlay C, Tabone MD, Pacquement H, Lervat C, Gentet JC, Schmitt C, Gaspar N, Brugières L. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma. 2014;2014:475067. doi: 10.1155/2014/475067. Epub 2014 Feb 04. PMID: 24672280; PMCID: PMC3941142.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 2014;2014:475067. doi: 10.1155/2014/475067. Epub 2014 Feb 04.

High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.

Sarcoma

Perrine Marec-Berard, Céline Segura-Ferlay, Marie-Dominique Tabone, Helene Pacquement, Cyril Lervat, Jean-Claude Gentet, Claudine Schmitt, Nathalie Gaspar, Laurence Brugières

Affiliations

  1. Institute for Paediatric Haematology and Oncology, Leon Bérard Cancer Centre, University of Lyon, 1 Place Joseph Renaut, 69008 Lyon, France.
  2. Unit of Biostatistics, Leon Bérard Cancer Centre, University of Lyon, 69008 Lyon, France.
  3. Department of Paediatric Haematology and Oncology, Hôpital Armand Trousseau, 75012 Paris, France.
  4. Department of Paediatrics, Curie Institute, 75248 Paris, France.
  5. Department of Paediatrics, Children's Hospital, 59037 Lilles, France.
  6. Department of Paediatrics, La Timone Hospital, 13385 Marseille, France.
  7. Department of Paediatrics, Children's Hospital, 54000 Nancy, France.
  8. Department of Paediatrics, Gustave Roussy Institute, 94805 Villejuif, France.

PMID: 24672280 PMCID: PMC3941142 DOI: 10.1155/2014/475067

Abstract

Introduction. Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years. We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in 45 children with relapsed osteosarcoma. Patients and Methods. Between 1992 and 2004, 53 patients received HD thiotepa (900 mg/m(2)) followed by ASCT in 6 centres. Eight patients were excluded from analysis, and we retrospectively reviewed the clinical radiological and anatomopathological patterns of the 45 remaining patients. Results. Sixteen girls and 29 boys (median age, 15.9 years) received HD thiotepa after initial progression of metastatic disease (2), first relapse (26), and second or third relapse (17). We report 12 radiological partial responses and 9 of 31 histological complete responses. Thirty-two patients experienced further relapses, and 13 continued in complete remission after surgical resection of the residual disease. Three-year overall survival was 40%, and 3-year progression-free survival was 24%. Delay of relapse (+/- 2 years from diagnosis) was a prognostic factor (P = 0.011). No acute toxic serious adverse event occurred. Conclusion. The use of HD thiotepa and ASCT is feasible in patients with relapsed osteosarcoma. A randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.

References

  1. Bone Marrow Transplant. 1992 Aug;10(2):171-5 - PubMed
  2. Pediatr Blood Cancer. 2014 Feb;61(2):238-44 - PubMed
  3. Ann Oncol. 2011 May;22(5):1228-1235 - PubMed
  4. Bone Marrow Transplant. 1998 Dec;22 Suppl 5:S37-40 - PubMed
  5. N Engl J Med. 2003 Jul 3;349(1):7-16 - PubMed
  6. Arch Surg. 1989 Jan;124(1):122-6 - PubMed
  7. J Clin Oncol. 1994 Dec;12(12):2614-20 - PubMed
  8. Bone Marrow Transplant. 1991 Nov;8(5):369-76 - PubMed
  9. J Clin Oncol. 1989 Feb;7(2):245-9 - PubMed
  10. J Pediatr Hematol Oncol. 2002 May;24(4):250-5 - PubMed
  11. Bone Marrow Transplant. 1999 Sep;24(6):609-15 - PubMed
  12. Semin Oncol. 1990 Feb;17(1 Suppl 3):2-6 - PubMed
  13. Crit Rev Oncol Hematol. 2002 Feb;41(2):129-40 - PubMed
  14. Sarcoma. 2012;2012:704872 - PubMed
  15. J Clin Oncol. 1996 May;14(5):1473-83 - PubMed
  16. Acta Oncol. 2005;44(7):748-55 - PubMed
  17. Bone Marrow Transplant. 2001 May;27(9):933-7 - PubMed
  18. Cancer. 1981 Oct 1;48(7):1522-7 - PubMed
  19. Cancer. 1995 Mar 1;75(5):1084-93 - PubMed
  20. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):689-95 - PubMed
  21. J Clin Oncol. 2002 Feb 1;20(3):776-90 - PubMed
  22. Br J Cancer. 1977 Jan;35(1):1-39 - PubMed
  23. Bone Marrow Transplant. 1994 Oct;14(4):665-6 - PubMed
  24. Bone Marrow Transplant. 1998 Jul;22(1):7-12 - PubMed
  25. Bone Marrow Transplant. 1992 Apr;9(4):227-33 - PubMed
  26. Cancer Chemother Pharmacol. 1987;19(2):143-8 - PubMed
  27. Invest New Drugs. 1996;13(4):337-42 - PubMed
  28. J Clin Oncol. 2002 Apr 15;20(8):2150-6 - PubMed
  29. J Clin Oncol. 2005 Jan 20;23(3):559-68 - PubMed
  30. Eur J Cancer. 2007 Mar;43(4):752-61 - PubMed
  31. Curr Opin Oncol. 2004 Mar;16(2):120-5 - PubMed
  32. Curr Opin Pediatr. 1997 Feb;9(1):55-69 - PubMed
  33. Cancer. 2005 Sep 1;104(5):1100-9 - PubMed
  34. J Clin Oncol. 2003 Feb 15;21(4):710-5 - PubMed
  35. Bone Marrow Transplant. 1998 Sep;22(6):535-40 - PubMed
  36. Arch Pathol Lab Med. 1977 Jan;101(1):14-8 - PubMed

Publication Types